Levonorgestrel API Market Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2022 to 2028

The global levonorgestrel API market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Levonorgestrel is in a class of medications called progestins. It works by preventing the release of an egg from the ovary. The long-active contraceptive API and intrauterine devices are anticipated to drive the growth of the market owing to their usage and several advantages. According to the cross-sectional study conducted by Biomedcentral, the prevalence of the long-acting contraceptive method usage was 23.0%. The most common reasons for preferring long-acting contraceptive methods were longer protection and effectiveness. Moreover, according to National Center for Biotechnology Information (NCBI), long-acting contraceptives API are effective means of birth control that can improve women’s overall health and readiness.

The long-acting contraceptives use increased from 21.9% to 23.9% from 2016 through 2019. The prevalence of uterine devices (IUDs) was greater than implants and IUDs also had a higher probability of continuation than implants. At 12 months, the continuation for IUDs was 81.0% compared to 73.0% for implants. Thus, the increased use of long-acting contraceptive API is anticipated to have a positive impact on overall health, further driving the demand for the levonorgestrel API market during the forecast period.

The growing application of New Day levonorgestrel 1.5mg is anticipated to drive the growth of the levonorgestrel API market.  It is coined under the human otc drug label category for emergency contraception. The drug is packaged by Northstar Rx LLC. A new day is one tablet with levonorgestrel, a hormone that has been used in many birth control pills. The drug contains several ingredients including magnesium state, lactose monohydrate, pregelatinized starch, polyvinyl alcohol, titanium dioxide, and others. Similarly, New Preventeza is an emergency contraceptive for the prevention of pregnancy. New Preventeza is a levonorgestrel tablet, a 1.5 mg over-the-counter tablet developed by Combe Inc. Thus, such applications are anticipated to drive the demand for the global levonorgestrel API market during the forecast period (2022-2028).

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Bayer AG, Hubei Gedian Humanwell Pharmaceutical Co. Ltd, ASG Biochem Pvt. Ltd., and Lupin Ltd. among others

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Levonorgestrel API Market Report by Segment

By Type

• Long-Acting Contraceptive API
• Short-Acting Contraceptive API

By Application

• Levonorgestrel Tablet
• Mixture Products
• Hormone Releasing IUD
• Others